C4 Therapeutics, Inc. (CCCC) Free cash flow
- Free cash flow · 12 months (USD): Value $-85.39M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -243.71%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-85.39M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-84.87M − $523.00K ≈ $-85.39M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -243.71% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-85.39M ÷ $35.04M × 100 ≈ -243.71% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-84.87M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.84× | Operating cash flow / net income. Period ending 2026-06-30. $-84.87M ÷ $-101.42M ≈ 0.84× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -84.87M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 523.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -85.39M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 35.04M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -101.42M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-85.39M | (m) | $-84.87M | $523.00K | (m) | $35.04M | (m) | $-101.42M | (m) | (m) | -243.71% | 0.84× |
| 2026-03-31 | $-96.02M | (m) | $-95.35M | $671.00K | (m) | $34.86M | (m) | $-103.80M | (m) | (m) | -275.45% | 0.92× |
| 2025-12-31 | $-99.30M | (m) | $-98.69M | $607.00K | (m) | $35.95M | (m) | $-104.99M | (m) | (m) | -276.24% | 0.94× |
| 2025-09-30 | $-95.07M | (m) | $-94.48M | $592.00K | (m) | $30.11M | (m) | $-119.08M | (m) | (m) | -315.77% | 0.79× |
| 2025-06-30 | $-87.58M | (m) | $-87.41M | $168.00K | (m) | $34.24M | (m) | $-111.58M | (m) | (m) | -255.77% | 0.78× |
| 2025-03-31 | (m) | (m) | $-80.32M | (m) | (m) | $39.78M | (m) | $-103.28M | (m) | (m) | (m) | 0.78× |
| 2024-12-31 | $-65.34M | (m) | $-65.16M | $180.00K | (m) | $35.58M | (m) | $-105.32M | (m) | (m) | -183.61% | 0.62× |
| 2024-09-30 | $-71.58M | (m) | $-71.23M | $341.00K | (m) | $33.67M | (m) | $-105.50M | (m) | (m) | -212.59% | 0.68× |
| 2024-06-30 | $-78.76M | (m) | $-77.81M | $954.00K | (m) | $29.38M | (m) | $-107.87M | (m) | (m) | -268.10% | 0.72× |
| 2024-03-31 | $-92.95M | (m) | $-91.83M | $1.12M | (m) | $20.04M | (m) | $-126.07M | (m) | (m) | -463.91% | 0.73× |
| 2023-12-31 | $-108.55M | (m) | $-106.84M | $1.71M | (m) | $20.76M | (m) | $-132.49M | (m) | (m) | -522.96% | 0.81× |
| 2023-09-30 | $-115.00M | (m) | $-111.96M | $3.04M | (m) | $20.35M | (m) | $-134.92M | (m) | (m) | -565.13% | 0.83× |
| 2023-06-30 | $-115.02M | (m) | $-109.27M | $5.75M | (m) | $16.03M | (m) | $-139.84M | (m) | (m) | -717.46% | 0.78× |
| 2023-03-31 | $-118.38M | (m) | $-112.47M | $5.91M | (m) | $27.20M | (m) | $-131.34M | (m) | (m) | -435.21% | 0.86× |
| 2022-12-31 | $-111.44M | (m) | $-105.94M | $5.50M | (m) | $31.10M | (m) | $-128.18M | (m) | (m) | -358.36% | 0.83× |
| 2022-09-30 | $-106.60M | (m) | $-102.48M | $4.12M | (m) | (m) | (m) | $-106.65M | (m) | (m) | (m) | 0.96× |
| 2022-06-30 | $-93.63M | (m) | $-92.82M | $810.00K | (m) | (m) | (m) | $-99.37M | (m) | (m) | (m) | 0.93× |
| 2022-03-31 | $-89.66M | (m) | $-88.63M | $1.03M | (m) | (m) | (m) | $-94.54M | (m) | (m) | (m) | 0.94× |
| 2021-12-31 | $-88.24M | (m) | $-86.97M | $1.28M | (m) | (m) | (m) | $-83.89M | (m) | (m) | (m) | 1.04× |
| 2021-09-30 | $-84.35M | (m) | $-82.89M | $1.46M | (m) | (m) | (m) | $-90.03M | (m) | (m) | (m) | 0.92× |
| 2021-06-30 | $-80.67M | (m) | $-78.92M | $1.74M | (m) | (m) | (m) | $-87.18M | (m) | (m) | (m) | 0.91× |
| 2021-03-31 | $-76.40M | (m) | $-75.52M | $887.00K | (m) | (m) | (m) | $-75.39M | (m) | (m) | (m) | 1.00× |
| 2020-12-31 | $-67.90M | (m) | $-67.25M | $650.00K | (m) | (m) | (m) | $-66.33M | (m) | (m) | (m) | 1.01× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $54.27M | (m) | $55.61M | $1.35M | (m) | (m) | (m) | $-34.10M | (m) | (m) | (m) | -1.63× |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |